Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

ARK Invest deployed over $10M in CRISPR Therapeutics and PayPay Corp on March 12, while cutting positions in Teradyne and Ionis Pharmaceuticals.

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Investing.com -- CRISPR Therapeutics AG (NASDAQ:CRSP)股价周二下跌6.75%,此前该公司宣布拟发行3.5亿美元可转换优先债券。 这家基因编辑公司表示,计划根据《证券法》第144A条规则,向合格机构买家私募发行2031年到期的可转换优先债券。该公司还预计将授予初始购买者一项选择权,可额外购买最多5,250万美元本金总额的债券。 这些债券将是该公司的 ...

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

CRISPR Therapeutics (NasdaqGM:CRSP) has announced a $350 million offering of convertible senior notes. The securities are a ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...